WEEKLY e-ALERT  [ PREMIUM EDITION ]
Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
Editor´s Picks
Why China Will Capitalize on Groundbreaking Healthcare Solutions Before The West(2/13/2018 )  (Premium)
  This Forbes article by Ben Shobert argues that "China has the potential to design its healthcare data policies today in a way that make it the best place to do cutting edge AI, machine learning and natural language processing research".
How Tencent's Medical Ecosystem Is Shaping the Future of China's Healthcare(2/13/2018 )  (Premium)
  This Technode article by Linda Lew describes how Tencent, China's largest internet company by market capitalization, will transform the country's healthcare, armed with government endorsements, the most used app in China, new AI medical imaging technology, and tons of cash to invest in medical startups.
GSK's Digital Strategies for Reaching New Buyers in China(2/13/2018 )  (Premium)
  From suggesting Sensodyne for foods featured in TV shows to mining Alibaba data, GSK's Cindy Lau explains the pharma group's digital strategy and O2O marketing tactics in this Campaign Asia article by Song Chen Kang.
The Chinese Pharmaceutical Industry: Winners and Losers 2017(2/12/2018 )  (Premium)
  This PharmExec article by Jin Zhang of LakePharma reports that "2017 was a year of great achievement for the Chinese pharma ndustry. Its total market value increased 137.22%; pharmaceutical products in all sectors exceeded $150 mln in sales; R&D investment fully blossomed; and in Q3/2017, eight products received their production approvals and 17 were greenlighted for clinical trials."
Industry News
MOLOGEN Signs Deal with ONCOLOGIE for Lead Compound Lefitolimod(2/13/2018 )  (Premium)
  MOLOGEN AG announced on February 13 the signing of a license deal for the Chinese territory and a global co-development agreement with ONCOLOGIE Inc. for its lead compound lefitolimod.
GNC Announces $300M Partnership with Harbin Pharma(2/13/2018 )  (Premium)
  GNC announced a strategic partnership and joint venture agreement with China's Harbin Pharmaceutical Group. Also known as Hayao, the company will invest $300 million in GNC, a Pittsburgh-based nutrition retailing chain and become the single largest shareholder,
India Pharma Companies See Growing Opportunities in China following Regulatory Reform(2/13/2018 )  (Premium)
  Dr Reddy's Laboratories (DRL) is expanding its presence in China, the world¡¯s second-largest pharmaceutical market, where other drug manufacturers such as Cipla and Lupin are exploring opportunities, according to an article of Indian media Business Standard.
GC Pharma and Lee's Pharm Enter into China Licensing Agreement for Anticoagulant Candidate(2/13/2018 )  (Premium)
  GC Pharma and Lee's Pharma announced on February 13 that they have entered into an agreement granting Lee's Pharm exclusive rights to develop and commercialise GCC-4401C, GC Pharma's investigational oral Factor Xa inhibitor anticoagulant for thromboembolic disease.
MSD Files NDA for Anticancer Keytruda in China(2/13/2018 )  (Premium)
  MSD is reported to have submitted the new drug application (NDA) for anticancer Keytruda in China, three months after global rival Bristol-Myers Squibb applied to sell a similar drug in the lucrative market.
Regulatory News
CFDA Releases List of Reference Formulations for Generic Drug Equivalence Studies (13th Batch)(2/14/2018 )  (Premium)
  The 13th batch of the list is composed of 53 reference drug products which are sourced from domestically produced originator drugs, imported drugs and U.S./EU/Japanese Orange Books.
CFDA Seeks Comments on Draft Document for Matters Related to Import Drug Registration(2/13/2018 )  (Premium)
  The General Office of the CFDA publicized a new draft document, Announcement for Matters Related to Import Drug Re-registration, on February 21 and is now soliciting public comments before March 2.
CFDA Publishes Its 2018 Legislation Plan(2/12/2018 )  (Premium)
  The CFDA published its 2018 legislation plan on February 12. According to the plan, the agency plans to work on 36 legislation projects including three laws, three regulations and 31 rules in the year of 2018.
CDE Solicits Comments on the General Requirements on Batch Production Size for Registration of Chemical Generic Drugs(2/12/2018 )  (Premium)
  The Center for Drug Evaluation under the CFDA (CDE) released a draft of the General Requirements on Batch Production Size for Registration of Chemical Generic Drugs on February 12 and is not seeking public comments.
General Health
British Government Announces Healthcare Deals with China Worth Over GBP 500M(2/14/2018 )  (free)
  It has been a momentous month for healthcare deals between the UK and China, with the announcement of numerous collaborations by UK companies in healthcare and life sciences with their Chinese partners.
China Reviews Achievements of the BMI System and Medical Assistance Program for the Poor in 2017(2/14/2018 )  (Premium)
  China's basic medical insurance system now covers 1.35 billion people, according to the National Health and Family Planning Commission. The enrollment rate of the BMI has been steady and held at 95% of the population in 2017, said WANG Hesheng, Vice Minister of NHFPC, at a press conference on Feb 12. Meanwhile, the critical illness insurance scheme covers 1.05 billion people, said Wang.
Legal/IPR News
UK Investigators Ask for New Info from GSK Relating to Its China Corruption Scandal(2/13/2018 )  (Premium)
  GlaxoSmithKline's China bribery imbroglio is the scandal that just won't die. After having paid more than half a billion dollars to lay to rest investigations by Chinese and U.S. authorities, the U.K. drugmaker has now been asked for new info from fraud investigators in its home country.
Product/R&D News
China's R&D Spending at Record High in 2017(2/14/2018 )  (Premium)
  According to a joint report published by the National Bureau of Statistics, the Ministry of Science and Technology and the Ministry of Finance, China's R&D investments totalled 1.75tn yuan (US$276bn) last year - up 11.6 percent year-on-year, Chinese newspaper Beijing Business Today reported on February 14.
BeiGene Presents Preliminary Phase 1 Data on Tislelizumab in Patients with Urothelial Carcinoma(2/13/2018 )  (Premium)
  BeiGene presented preliminary clinical data from patients with urothelial carcinoma (UC) enrolled in an ongoing Phase 1 clinical trial of tislelizumab, an investigational anti-PD-1 antibody, at the 2018 Genitourinary Cancers Symposium in San Francisco.
Chi-Med Enrolls 527 Patients in Pivotal Phase III FALUCA Trial of Fruquintinib in Lung Cancer(2/13/2018 )  (free)
  Hutchison China MediTech Limited (Chi-Med) (AIM/Nasdaq: HCM) announced on February 13 that it has completed patient enrollment of FALUCA, its Phase III pivotal trial of fruquintinib in advanced, third-line, non-small cell lung cancer (NSCLC) patients in China.
People in the News
Recent Executive Moves(2/15/2018 )  (Premium)
  Recent Chinese pharma-related executive moves at compnaies including Takeda China, Ferring China, Roche and IQVIA.
© Wicon International Group¡¡Support by: www.heightow.com Home | Site map | Contact Us | Links